Filter By Category
Archives
Share on -
ACASUNLIMAB
Generic Name: ACASUNLIMAB
ABSTRACT -
Acasunlimab, also known as INBRX-106, is an investigational hexavalent OX40 agonist antibody designed to activate the OX40 costimulatory pathway. OX40 signaling can support T-cell proliferation, survival, and antitumor immune function. Acasunlimab has been studied alone and in combination with immune checkpoint inhibitors or other anticancer therapies in patients with advanced solid tumors. It is not established as a routine approved treatment for general clinical use.
DOSAGE –
Acasunlimab is an investigational immuno-oncology agent and should only be administered under an approved clinical trial protocol or by qualified oncology specialists.
- Studied by intravenous infusion in clinical research settings.
- Dosing schedules vary by study, cohort, tumor type, and combination regimen.
- Some studies have evaluated administration once every three or six weeks, depending on protocol design.
- No standard commercial dose has been established for routine medical use.
- Dose interruption, delay, or discontinuation may be required for immune-related or infusion-related toxicity.
- Participants should follow all protocol-specific dosing, monitoring, and follow-up instructions.
SIDE EFFECTS –
Reported or potential side effects may include:
- Infusion-related reactions
- Fatigue
- Fever or chills
- Rash or itching
- Diarrhea
- Nausea or decreased appetite
- Cough or shortness of breath
- Headache
- Joint or muscle pain
- Elevated liver enzymes or other laboratory changes
- Immune-related inflammation affecting organs such as skin, intestine, liver, lung, or endocrine glands
- Infections
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the medicine.)
- Skin rash
- Itching
- Hives
- Swelling of the face, lips, tongue, or throat
- Difficulty breathing or wheezing
- Chest tightness
- Severe dizziness or fainting
- Rapid heartbeat
- Anaphylaxis or severe hypersensitivity reaction
DRUG INTERACTIONS–
Formal interaction data are limited because acasunlimab remains investigational. Caution should be exercised when used with:
- Other immunotherapies, especially checkpoint inhibitors, due to additive immune-related toxicity
- High-dose corticosteroids or immunosuppressive drugs that may reduce immune activation
- Other anticancer therapies with overlapping liver, lung, gastrointestinal, or marrow toxicity
- Live or live-attenuated vaccines unless permitted by protocol
- Other investigational agents or herbal immune-stimulating products
- Medicines that complicate management of fever, infection, or organ inflammation
Patients should inform healthcare providers about all prescription medicines, non-prescription medicines, vitamins, herbal products, vaccines, and supplements being used.
PRECAUTIONS –
- Use only in specialist oncology or clinical trial settings.
- Assess baseline organ function, autoimmune history, infection status, and performance status.
- Monitor for infusion reactions and immune-related adverse events involving skin, bowel, liver, lung, endocrine organs, and other tissues.
- Use caution in patients with active autoimmune disease, active infection, organ transplant history, or significant immune suppression.
- Pregnancy and breastfeeding safety have not been established; effective contraception may be required.
- Patients should promptly report fever, rash, diarrhea, breathing difficulty, jaundice, severe fatigue, or new neurologic symptoms.
WARNINGS –
- Acasunlimab is investigational and has not been established for routine general medical use.
- Immune-activating anticancer antibodies may cause serious or life-threatening immune-mediated adverse reactions.
- Severe infusion reactions may require urgent treatment and permanent discontinuation.
- Clinical use should be supervised by trained healthcare professionals with access to emergency care.
- Keep out of reach of children.
- In case of severe adverse reaction or breathing difficulty, seek immediate medical attention.
- Patients should report unusual symptoms or side effects to their healthcare provider or clinical investigator promptly.
Share on -
. Developed by